Fed’s Powell opens door to potential rate cuts at Jackson Hole
Investing.com -- Coloplast (CSE:COLOb) on Tuesday delivered in-line third-quarter results with 6.6% organic sales growth matching consensus estimates and an EBIT margin of 27.5%, slightly above the expected 27.3%.
The Danish medical device company saw strong performance in most business segments, with Ostomy growing 6%, Continence 8%, and Voice & Respiratory Care leading at 9%. Interventional Urology showed reassuring 4% growth, driven by good momentum in US Men’s Health.
Wound Care underperformed with 4% growth versus the expected 10%, primarily due to a product recall in China for Biatain Adhesive foam dressings, creating a negative sales impact of approximately DKK20 million in Q3.
Kerecis also experienced a slowdown, growing 17% in the quarter due to LCD delay issues.
Coloplast maintained its full-year 2024/25 guidance of approximately 7% organic sales growth and an EBIT margin of 27-28%. This outlook incorporates the DKK80 million impact from the Wound Care product recall and neutral foreign exchange effects, offset by strong momentum in other business areas.
The company announced an immediate organizational restructuring into two units: Chronic Care (encompassing Ostomy, Continence, and Voice & Respiratory Care) and Acute Care (covering Interventional Urology and Wound Care). Each unit will be led by newly-appointed internal leaders.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.